This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Bempeg is a new formulation of an interleukin-2-based drug Proleukin (aldesleukin), sold by Clinigen, that extends its action in the body and according to its developer overcomes a safety issue that has pegged back sales of the original drug. The post Nektar lifted by Merck alliance for bempeg, new trialfunding appeared first on.
National Institutes of Health failed to ensure that results of roughly half of clinical trialsfunded by the agency — both those conducted by its own scientists and outside researchers — were reported to a federal database during a recent two-year period, a new government review has found.
The trials, funded by the American Heart Association, will harness the companyâs Verisense wearable sensor platform to examine brain-heart health links.
The first patients have been dosed in a trial of two AstraZeneca antibodies, collectively known as AZD7442, that are being developed to both treat and prevent coronavirus infections. The phase 1 trial – funded by the US government – will take place in the UK and will test the safety of AZD7442 and its pharmacokinetic profile.
The ORP collaborates with external funders to develop peer-reviewed grant opportunities for oncology researchers to improve cancer care. They facilitate funding of both investigator-initiated research involving therapeutics as well as quality improvement initiatives aimed at improving cancer care systemically.
On June 22, 2022, the Canadian Institutes of Health Research ( CIHR ) announced the launch of the Clinical TrialsFund ( CTF ), which will inject funding into Canada’s clinical trials environment. The Clinical TrialsFund. Clinical Trials Training Platforms ( CTTP ).
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content